The U.S. FDA gave Bot Image Inc. a coveted threefer with 510(k) clearance for its Prostatid artificial intelligence (AI) software for detection, diagnosis and monitoring of prostate cancer using both standard MRI and a non-invasive bi-parametric MRI, which does not require a contrast agent.
Cardio Diagnostics Holding Inc. launched Precisionchd, a blood test for the early detection of coronary heart disease. The test will initially be available for existing customers, with nationwide rollout to follow shortly thereafter, the company said.
Epigenetic testing company Trudiagnostic LLC has linked up with Rejuve.AI, an artificial intelligence (AI)-powered longevity research network, to develop more accurate tools for predicting chronological age. Specifically, the collaboration seeks to shed new light on the biology of aging and connectedness of DNA methylation (DNAm), metabolomics and proteomics.
The European Union’s (EU) Artificial Intelligence Act (AI Act) drew a fair amount of criticism when it was first released, but Team-NB, the association of notified bodies (NBs) for the EU, has weighed in with some less than flattering observations. The group’s position paper on the legislation said that the act would not only up-classify some artificial intelligence algorithms to a higher risk class but would also resurrect the backlog of applications because of burdensome new requirements for NBs, thus exacerbating an existing crisis of med tech availability in the EU.
Nuralogix Corp. is taking its selfie-based health monitoring platform to the next level, offering continuous health and vital signs tracking during video calls. The launch of Anura Telehealth is the newest addition its Anura app, which uses video cameras on smartphones and other consumer devices to extract facial blood flow information and provide a personalized snapshot of health and wellness.
Numares Health AG received $21.2 million from the European Investment Bank (EIB) in support to its automated and software based IVD platform for obtaining high-quality nuclear magnetic resonance metabolomics data from blood or urine biopsy samples.
The U.S. FDA managed to wrap up a guidance for clinical decision support (CDS) products after several years, one of several projects the agency was liable for in the area of digital health. While a much-needed draft guidance for change control for artificial intelligence algorithms made the guidance agenda for the FDA’s new fiscal year, that draft is only a B draft guidance priority, suggesting that a final guidance might not emerge until calendar year 2024, possibly later.
Biogen Inc. presented new data showing how applying artificial intelligence (AI), machine learning (ML) and radiomics can produce actionable insights on multiple sclerosis (MS) disease progression. The results, released at this week’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, could help to advance new digital health tools to improve monitoring and quality of life of MS patients.
Researchers based at the City University of New York (CUNY) have designed a deep learning artificial intelligence (AI) model that can improve preclinical predictions of drug responses in humans. As outlined in the Oct. 17, 2022, online issue of Nature Machine Intelligence, the researchers believe their model – a context-aware deconfounding autoencoder (CODE-AE) – can help improve the quality of early drug response prediction and help reduce subsequent clinical trial failures.
Researchers based at the City University of New York (CUNY) have designed a deep learning artificial intelligence (AI) model that can improve preclinical predictions of drug responses in humans. As outlined in the Oct. 17, 2022, online issue of Nature Machine Intelligence, the researchers believe their model – a context-aware deconfounding autoencoder (CODE-AE) – can help improve the quality of early drug response prediction and help reduce subsequent clinical trial failures.
RSS
